In patients with advanced Parkinson disease, levodopa/carbidopa formulated as a gel suspension (Duodopa) permits continuous delivery into the small intestine using a portable pump, resulting in less variability in levodopa concentrations and fewer motor fluctuations and dyskinesias than with oral levodopa administration. This is a retrospective analysis of the long-term clinical experience with this agent.
All but 1 of the patients who had received enteral levodopa infusion treatment between January 1, 1991, and June 30, 2002, consented to a review of their hospital charts.
Of the 65 patients with initial testing of the treatment, 86% opted for continued treatment via percutaneous endoscopic gastrostomy or gastrojejunostomy. Total exposure to levodopa infusion was 216 patient-years (mean, 3.7 years). Maximum treatment duration was 10.7 years. Fifty-two patients were treated for 1 year or longer. The adverse effect profile of levodopa/carbidopa infusion was similar to that observed with oral administration of levodopa. Seven deaths occurred, all considered unrelated to the treatment. Intestinal tube problems, including dislocation of the intestinal tube to the stomach, were the most common technical problem, occurring in 69% of the patients during the first year. The optimal daily dose of levodopa decreased by an average of 5% during follow-up.
The safety of enteral infusion of levodopa/carbidopa formulated as a gel suspension was found acceptable. For most patients, the technical challenges posed by the enteral infusion system were offset by the improvement in motor fluctuations and dyskinesias offered by this technique.
*Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala; †Tommy Lewander Consulting, Uppsala, Sweden; ‡Clinical Neuroscience Center, Wayne State University School of Medicine, Southfield, Michigan; §Department of Neurology, Ullevål University Hospital, Oslo, and HØKH-Helse Øst Health Services Research Centre, Akershus University Hospital, Lørenskog, Norway.
Supported by NeoPharma AB, Uppsala, Sweden.
Sten-Magnus Aquilonius is one of the founders of NeoPharma AB, acquired by Solvay Pharmaceuticals in 2005. Peter LeWitt has served as consultant to NeoPharma AB. Dag Nyholm and Tommy Lewander serve as consultants to Solvay Pharmaceuticals; Tommy Lewander was the medical director of NeoPharma AB during the course of the study. Anders Johansson has received remuneration from Solvay Pharmaceuticals for giving occasional presentations. Christofer Lundqvist has been invited by NeoPharma AB to give presentations of the treatment method at a number of meetings and has also received project sponsorship from Solvay Pharma AS, Norway. NeoPharma AB, subsequently Solvay Pharmaceuticals, have taken part in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, and the approval of the manuscript.
Address correspondence and reprint requests to Dag Nyholm, MD, PhD, Department of Neuroscience, Neurology, Uppsala University Hospital, SE-75185 Uppsala, Sweden; E-mail: email@example.com